Defining targets for investigating the pharmacogenomics adverse drug reactions to antifungal agents

Pharmacogenomics

Volumn 9, Issue 5, 2008, Pages 561-584

  Meletiadis, Joseph ^a,b   Chanock, Stephen ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Antifungal drug; Mechanisms of toxicity; Pharmacogenomics; SNP

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; BENZODIAZEPINE DERIVATIVE; CASPOFUNGIN; CLOTRIMAZOLE; CYTOCHROME P450 2C19; DRUG METABOLIZING ENZYME; ECHINOCANDIN; FLUCYTOSINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIDAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN; MEVINOLIN; MICONAZOLE; MULTIDRUG RESISTANCE PROTEIN; NYSTATIN; POSACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; TOLL LIKE RECEPTOR; UNINDEXED DRUG; VORICONAZOLE;

ABNORMAL LABORATORY RESULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APPLICATION SITE REACTION; ARTHRALGIA; BLURRED VISION; BONE MARROW SUPPRESSION; CHILL; CHOLESTASIS; COLOR VISION; CONCENTRATION LOSS; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DIARRHEA; DISEASE PREDISPOSITION; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG DNA INTERACTION; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; DYSGEUSIA; DYSPEPSIA; ENDOCRINE DISEASE; EPIGASTRIC FULLNESS; ETHNIC DIFFERENCE; FATIGUE; FEVER; FOOT EDEMA; GASTRITIS; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GYNECOMASTIA; HALLUCINATION; HEPATOBILIARY DISEASE; HISTAMINE RELEASE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOGLYCEMIA; HYPOKALEMIA; INDUCED HYPOTENSION; LIBIDO DISORDER; LIVER CELL DAMAGE; LIVER FUNCTION; LIVER TOXICITY; MAST CELL; METABOLIC ACIDOSIS; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OLIGOSPERMIA; PANCREATITIS; PHARMACOGENOMICS; PHLEBITIS; PHOTOPHOBIA; POTASSIUM BLOOD LEVEL; PRURITUS; RASH; REVIEW; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; TASTE DISORDER; THROMBOCYTOPENIA; TOXICOGENETICS; VISUAL DISORDER; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 44949204427     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.5.561     Document Type: Review

References (209)

1. Lazarou, J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
2. Ingelman-Sundberg M: Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250, 186-200 (2001).
3. Meyer UA, Gut J: Genomics and the prediction of xenobiotic toxicity. Toxicology 181-182, 463-466 (2002).
4. Park BK, Pirmohamed M: Toxicogenetics in drug development. Toxicol. Lett. 120, 281-291 (2001).
5. Park BK, Pirmohamed M, Kitteringham NR: Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969-988 (1998).
6. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP: Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301-306 (1997).
7. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
8. van Schaik RH: Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. Ther. Drug Monit. 26, 236-240 (2004).
9. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG: Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 128, 281-285 (2000).
10. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91, 2001-2008 (1999).
11. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
12. Ratain MJ, Mick R, Berezin F et al.: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther. 50, 573-579 (1991).
13. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad. Sci. USA 97, 3473-3478 (2000).
14. Severino G, del Zompo M: Adverse drug reactions: role of pharmacogenomics. Pharmacol. Res. 49, 363-373 (2004).
15. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
16. Maher B, Alfirevic A, Vilar FJ et al.: TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16, 2013-2018 (2002).
17. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA: The association of atopy with a gain-of-function mutation in the α subunit of the interleukin-4 receptor. N. Engl. J. Med. 337, 1720-1725 (1997).
18. Lasser KE, Allen PD, Woolhandler SJ et al.: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220 (2002).
19. Meletiadis J, Chanock S, Walsh TJ: Human pharmacogenomic variations and their implications for antifungal efficacy. Clin. Microbiol. Rev. 19, 763-787 (2006).
20. Groll AH, Piscitelli SC, Walsh TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44, 343-500 (1998).
21. Walsh TJ, Finberg RW, Arndt C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses-Study Group. N. Engl. J. Med. 340, 764-771 (1999).
22. Francis P, Walsh TJ: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. 15, 1003-1018 (1992).
23. Willems L, van der Geest R, de Beule K: Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 26, 159-169 (2001).
24. Ahmad SR, Singer SJ, Leissa BG: Congestive heart failure associated with itraconazole. Lancet 357, 1766-1767 (2001).
25. Goa KL, Barradell LB: Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50, 658-690 (1995).
26. Pappas PG, Kauffman CA, Perfect J et al.: Alopecia associated with fluconazole therapy. Ann. Intern. Med. 123, 354-357 (1995).
27. Johnson LB, Kauffman CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630-637 (2003).
28. Amichai B, Grunwald MH: Adverse drug reactions of the new oral antifungal agents - terbinafine, fluconazole, and itraconazole. Int. J. Dermatol. 37, 410-415 (1998).
29. Deresinski SC, Stevens DA: Caspofungin. Clin. Infect. Dis. 36, 1445-1457 (2003).
30. Sable CA, Nguyen BY, Chodakewitz JA, Dinubile MJ: Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis. 4, 25-30 (2002).
31. Groll AH, Walsh TJ: Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs 10, 1545-1558 (2001).
32. Bekersky I, Boswell GW, Hiles R et al.: Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm. Res. 16, 1694-1701 (1999).
33. Chandra P, Brouwer KL: The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21, 719-735 (2004).
34. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am. J. Med. 111, 528-534 (2001).
35. Risovic V, Sachs-Barrable K, Boyd M, Wasan KM: Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev. Ind. Pharm. 30, 767-774 (2004).
36. Ieiri I, Takane H, Hirota T, Otsubo K, Higuchi S: Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin. Drug Metab. Toxicol. 2, 651-674 (2006).
37. Cascorbi I: Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473 (2006).
38. Romanini D, Avalle G, Farruggia B, Nerli B, Pico G: Spectroscopy features of the binding of polyene antibiotics to human serum albumin. Chem. Biol. Interact. 115, 247-260 (1998).
39. Romanini D, Muller G, Pico G: Use of amphotericin B as optical probe to study conformational changes and thermodynamic stability in human serum albumin. J. Protein Chem. 21, 505-514 (2002).
40. Israili ZH, Dayton PG: Human α-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33, 161-235 (2001).
41. Kragh-Hansen U, Brennan SO, Galliano, M, Sugita O: Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations. Mol. Pharmacol. 37, 238-242 (1990).
42. Li JH, Xu JQ, Cao XM et al.: influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin. Chim. Acta 317, 85-92 (2002).
43. Vestberg K, Galliano M, Minchiotti L, Kragh-Hansen U: High-affinity binding of warfarin, salicylate and diazepam to natural mutants of human serum albumin modified in the C-terminal end. Biochem. Pharmacol. 44, 1515-1521 (1992).
44. Wasan KM, Conklin JS: Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. 24. 78-80 (1997).
45. Wasan KM, Wong JC, Corr T, Pritchard S: Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. Cancer Chemother. Pharmacol. 57, 120-124 (2006).
46. Wasan KM, Cassidy SM: Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87, 411-424 (1998).
47. Chavanet P, Joly V, Rigaud D et al.: Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 38, 963-968 (1994).
48. Kennedy AL, Wasan KM: Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. J. Pharm. Sci. 88, 1149-1155 (1999).
49. Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein G: Decreased toxity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J. Pharm. Sci. 83, 1006-1010 (1994).
50. Vertut-Doi A, Ohnishi SI, Bolard J: The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrob. Agents Chemoter. 38, 2373-2379 (1994).
51. Krieger M: The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis. Anal. Biochem. 135, 383-391 (1983).
52. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G: Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38, 223-227 (1994).
53. Chan DC, Barrett PH, Watts GF: Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. Clin. Sci. (Lond.) 107, 221-232 (2004).
54. Ye SQ, Kwiterovich PO Jr: Influence of genetic polymorphisms on responsiveness to dietary fat and cholesterol. Am. J. Clin. Nutr. 72, S1275-S1284 (2000).
55. Kwong M, Wasan KM: Cholesteryl ester transfer protein facilitates the movement of water-insoluble drugs between lipoproteins: a novel biological function for a well-characterized lipid transfer protein. Biochem. Pharmacol. 64, 1669-1675 (2002).
56. Fanos V, Cataldi L: Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12, 463-470 (2000).
57. Sabra R, Branch RA: Amphotericin B nephrotoxicity. Drug Saf. 5, 94-108 (1990).
58. Fanos V, Cataldi L: Renal transport of antibiotics and nephrotoxicity: a review. J. Chemoter. 13, 461-472 (2001).
59. Brajtburg J, Powderly WG, Kobayashi GS. Medoff G: Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Cbenwther. 34, 183-188 (1990).
60. Catella-Lawson F: Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology 57, S5-S7 (2001).
61. Hardie WD, Ebert J, Frazer M, Takahashi K, Badr K: The effect of thromboxane A2 receptor antagonism on amphotericin B-induced renal vasoconstriction in the rat. Prostaglandins 45, 47-56 (1993).
62. Mcguire TR, Trickier WJ, Hock L et al. Release of prostaglandin E-2 in bovine brain endothelial cells after exposure to three unique forms of the antifungal drug amphotericin-B: role of COX-2 in amphotericin-B: induced fever. Life Sci. 72, 2581-2590 (2003).
63. Orbe J, Beloqui O, Rodriguez, JA et al.: Profective effect of the G-765C COX-2 polymorphism on subdinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin. Chim. Acta 368, 138-143 (2006).
64. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A: Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38, 459-465 (1995).
65. Rogers PD, Pearson MM, Cleary JD, Sullivan DC, Chapman SW: Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J. Antimicrob. Chemother. 50, 811-817 (2002).
66. Rogers PD, Stiles JK, Chapman SW, Cleary JD: Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. J. Infect. Dis. 182, 1280-1283 (2000).
67. Simitsopoulou M, Roilides E, Dotis J et al.: Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob. Agents Chemother. 49, 1397-1403 (2005).
68. Sau K, Mambula SS, Latz E et al.: The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem. 278, 37561-37568 (2003).
69. Razonable RR, Henault M, Lee LN et al.: Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob. Agents Chemother. 49, 1617-1621 (2005).
70. Matsuo K, Hotokezaka H, Ohara N et al.: Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol. Immunol. 50, 337-347 (2006).
71. Leung TF, Tang NL, Wong GW, Fok TF: CD14 and toll-like receptors: potential contribution of genetic factors and mechanisms to inflammation and allergy. Curr. Drug Targets Inflamm. Allergy 4, 169-175 (2005).
72. Uematsu S, Akira S: The role of Toll-like receptors in immune disorders. Expert Opin. Biol. Ther. 6, 203-214 (2006).
73. Addas-Carvalho M, Salles TS, Saad ST: The association of cytokine gene polymorphisms with febrile non-hemolytic transfusion reaction in multitransfused patients. Transfus. Med. 16, 184-191 (2006).
74. Virta M, Hurme M, Helminen M: Increased frequency of interleukin-1β (-511) allele 2 in febrile seizures. Pediatr. Neurol. 26, 192-195 (2002).
75. Baronti R, Masini E, Bacciottini L, Mannaioni PF: Differential effects of amphotericin B and liposomal amphotericin B on inflammatory cells in vitro. Inflamm. Res. 51, 259-264 (2002).
76. Cleary JD, Schwartz M, Rogers PD, de Mestral J, Chapman SW: Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 23, 966-973 (2003).
77. Ghannoum MA, Kuhn DM: Voriconazole - better chances for patients with invasive mycoses. Eur. J. Med. Res. 7, 242-256 (2002).
78. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N: Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46, 235-243 (2006).
79. Imhof A, Schaer DJ, Schanz U, Schwarz U: Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly 136, 739-742 (2006).
80. Ikeda Y, Umemura K, Kondo K et al.: Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Pharmacol. Ther. 75, 587-588 (2004).
81. Mikus G, Schowel V, Drzewinska M et al.: Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther. 80, 126-135 (2006).
82. Purkins L, Wood N, Ghahramani P et al.: No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br. J. Clin. Pharmacol. 56(Suppl. 1). 30-36 (2003).
83. Rengelshausen J, Banfield M, Riedel KD et al.: Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther. 78, 25-33 (2005).
84. de Leon J, Susce MT, Murray-Carmichael E: The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol. Diagn. Ther. 10, 135-151 (2006).
85. Ebrey T, Koutalos Y: Vertebrate photoreceptors. Prog. Retin. Eye Res. 20, 49-94 (2001).
86. Madreperla SA, Johnson MA, Nakatani K: Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch. Ophthalmol. 112, 807-812 (1994).
87. Weleber RG, Shults WT: Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome. Arch. Ophthalmol. 99, 1568-1572 (1981).
88. Duvvuri S, Majumdar S, Mitra AK: Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 3, 45-56 (2003).
89. Hariprasad SM, Mieler WF Holz ER et al.: Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122, 42-47 (2004).
90. Shen YC, Wang MY, Wang CY et al.: Clearance of intravitreal voriconazole. Invest. Ophthalmol. Vis. Sci. 48, 2238-2241 (2007).
91. Garder S: Pharmacokinetics. In: Endophalmitis: Diagnosis and Management. Peyman GA, Lee PJ, Seal DV (Eds). Taylor & Francis, London, UK, 81-100 (2004).
92. Aukunuru JV, Sunkara G, Bandi N, Thoreson WB, Kompella UB: Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. 18, 565-572 (2001).
93. Kennedy BG, Mangini NJ: P-glycoprotein expression in human retinal pigment epithelium. Mol. Vis. 8, 422-430 (2002).
94. Holash JA, Stewart PA: The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res. 629, 218-224 (1993).
95. Mannermaa E, Vellonen KS, Urtti A: Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev. 58, 1136-1163 (2006).
96. Mejico LJ, Bergloeff J, Miller NR: New therapies with potential neuro-ophthalmologic toxicity. Curr. Opin. Ophthalmol. 11, 389-394 (2000).
97. Laties A, Zrenner E: Viagra (sildenafil citrate) and ophthalmology. Prog. Retin. Eye Res. 21, 485-506 (2002).
98. Lawrenson JG, Kelly C, Lawrenson AL, Birch J: Acquired colour vision deficiency in patients receiving digoxin maintenance therapy. Br. J. Ophthalmol. 86, 1259-1261 (2002).
99. + channels by cytochrome P-450 inhibitors. J. Biol. Chem. 267, 11789-11793 (1992).
100. 2+ store depletion in human platelets is more susceptible to cytochrome P-450 inhibitors than receptor-mediated calcium entry. Cell. Calcium 13, 553-564 (1992).
101. MacNeil S, Dawson RA, Crocker G et al.: Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity. Br. J. Dermatol. 128, 143-150 (1993).
102. Hegemann L, Toso SM, Lahijani KI, Webster GF, Ultto J: Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J. Invest. Dermatol. 100, 343-346 (1993).
103. Kanda N, Enomoto U, Watanabe S: Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J. Invest. Dermatol. 117, 1635-1646 (2001).
104. Stalla GK, Stalla J, von Werder K et al.: Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology 125, 699-706 (1989).
105. Surarit R, Shepherd MG: The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J. Med. Vet. Mycol. 25, 403-413 (1987).
106. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharamyces cerevisiae is modulated by calcium signalling. Mol. Microbiol. 46, 257-268 (2002).
107. Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J: Calcineurin A of Candida albicans. involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48, 959-976 (2003).
108. Turko IV, Ballard SA, Francis SH, Corbin JD: Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol. Pharmacol. 56, 124-130 (1999).
109. Lyman CA, Walsh TJ: Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44, 9-35 (1992).
110. Sugar AM, Alsip SG, Galgiani JN et al.: Pharmacology and toxicity of high-dose ketoconazole. Antimicrob. Agents Chemother. 31, 1874-1878 (1987).
111. Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C: The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin. Endocrinol. (Oxf.) 35, 163-168 (1991).
112. Miossec P. Archambeaud-Mouveroux F, Teissier MP: [Inhibition of steroidogenesis by ketoconazole. Therapeutic uses]. Ann Endocrinol. (Paris) 58, 494-502 (1997).
113. Kristensen VN, Borresen-Dale AL: Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat. Res. 462, 323-333 (2000).
114. Wang JM, Wu XL, You W et al.: Pharmacokinetic and pharmacodynamic studies of the effect of ketoconazole on reproductive function in male rats. Int. J. Androl. 15, 376-384 (1992).
115. Eid H, Mingfang L, Institoris E, Bodrogi I, Bak M: MRP expression of testicular cancers and its clinical relevance. Anticancer Res. 20, 4019-4022 (2000).
116. Melaine N, Lienard MO, Dorval I et al.: Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, Guinea pig, and human. Biol. Reprod. 67, 1699-1707 (2002).
117. Choo EF, Leake B, Wandel C et al.: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28, 655-660 (2000).
118. Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55, 3-29 (2003).
119. McNicol AM: Molecular aspects of adrenal tumours. Minerva Endocrinol. 20, 9-13 (1995).
120. Nooter K, Westerman AM, Flens MJ et al.: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1, 1301-1310 (1995).
121. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW: Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. 46, 160-165 (2002).
122. Kim RB, Wandel C, Leake B et al.: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16, 408-414 (1999).
123. von Moltke LL, Granda BW, Grassi JM, Greenblatt DJ: Multiple site interaction of triazolam and ketoconazole in mice role of P-glycoprotein (Abstract PI-106). Clin. Pharmacol. Ther. 65, 143 (1999).
124. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bilie J: The ATP binding cassette transporter gene CgCDR1 from Canadida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43, 2753-2765 (1999).
125. Stricker BH, Blok AP, Bronkhorst FB, van Parys GE, Desmet VJ: Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J. Hepatol. 3, 399-406 (1986).
126. Rodriguez RJ, Proteau PJ, Marquez BL et al.: Flavin-containing monooxygenase-mediated metabolism of N-deacetyl ketoconazole by rat hepatic microsomes. Drug Metab. Dispos. 27, 880-886 (1999).
127. Rodriguez RJ, Miranda CL: Isoform specificity of N-deacetyl ketoconazole by human and rabbit flavin-containing monooxygenases. Drug Metab. Dispos. 28, 1083-1086 (2000).
128. Rodriguez RJ, Buckholz CJ: Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding. Xenobiotica 33, 429-441 (2003).
129. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst. 92, 1295-1302 (2000).
130. Cashman JR: Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3, 325-339 (2002).
131. Hines RN, Luo Z, Hopp KA et al.: Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6). J. Pharmacol. Exp. Ther. 306(3), 1210-1218 (2003).
132. Daly AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17, 27-41 (2003).
133. Suzuki H, Sugiyama Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug, Deliv. Rev. 54, 1311-1331 (2002).
134. Oselin K, Mrozikiewicz PM, Gaikovitch E, Pahkla R, Roots I: Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. i Eur. J. Clin. Pharmacol. (2003).
135. Adriaenssens B, Roskams T, Steger P, van Steenbergen W: Hepatotoxicity related to itraconazole: report of three cases. Acta Clin. Belg. 56, 364-369 (2001).
136. Bronstein JA, Gros P, Hernandez E, Larroque P, Molinie C: Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin. Infect. Dis. 25, 1266-1267 (1997).
137. Terbinafine, product monograph. Sandoz, Dorval, Canada, 1-33 (1995).
138. Fernandes NF Geller SA, Fong TL: Terbinaftne hepatotoxicity: case report and review of the literature. Am. J. Gastroenterol. 93, 459-460 (1998).
139. Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC: Terbinafine-induced cholestatic liver disease. J. Hepatol. 24, 753-756 (1996).
140. Geubel AP: Drug-related biliary damage: a peculiar condition involving a genetic predisposition? Acta Gastroenterol. Belg. 61, 2-3 (1998).
141. Iverson SL, Uetrecht JP: Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem. Res. Toxicol. 14. 175-181 (2001).
142. Vermes A, Guchelaar HJ, Dankert J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob. Chemother. 46, 171-179 (2000).
143. Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J: An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. Chemotherapy 49, 17-23 (2003).
144. Vermes A, Guchelaar HJ, van Kuilenburg AB, Dankert J: 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study. Fundam. Clin. Pharmacol. 16, 39-47 (2002).
145. Sparreboom A, van Asperen J, Mayer U et al.: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl Acad. Sci. USA 94, 2031-2035 (1997).
146. Mayer U, Wagenaar E, Beijnen JH et al.: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr la P-glycoprotein. Br. J Pharmacol. 119, 1038-1044 (1996).
147. Guo Y, Kotova E, Chen ZS et al.: MRP8 (ABCC11) is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines, 2′3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)-adenine. J. Biol. Chem. 278(32), 29509-29514 (2003).
148. Jedlitschky G, Burchell B, Keppler D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275, 30069-30074 (2000).
149. Sampath J, Adachi M, Hatse S et al.: Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 4, E14 (2002).
150. Juszczynski P, Niewiarowski W, Krykowski E, Robak T, Warzocha K: Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia. Leuk. Lymphoma 43, 153-158 (2002).
151. Vermes A, van der Sijs H, Guchelaar HJ: Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 46, 86-94 (2000).
152. Gray JH, Owen RP, Giacomini KM: The concentrative nucleoside transporter family. SLC28. Pflugers Arch. 447(5), 728-734 (2004).
153. Lenz HJ, Leichman CG, Danenberg KD et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14, 176-182 (1996).
154. Metzger R, Leichman CG, Danenberg KD et al.: ERCC1 mRNA levels complement thymidyiate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin. Oncol. 16, 309-316 (1998).
155. Ladner RD, Lynch FJ, Groshen S et al.: dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res. 60, 3493-3503 (2000).
156. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio, RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47, 2203-2206 (1987).
157. Johnson MR, Wang K, Diasio RB: Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8, 768-774 (2002).
158. Mora-Duarte J, Betts R, Rotstein C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020-2029 (2002).
159. Benjamin DK Jr, Driscoll T, Seibel NL et al.: Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50, 632-638 (2006).
160. Oliver JM, Kepley CL, Ortega E, Wilson BS: Immunologically mediated signaling in basoplills and mast cells: finding therapeutic targets for allergic diseases in the human FcvarεR1 signaling pathway. Immunopharmacology 48, 269-281 (2000).
161. Rascu A, Repp P, Westerdaal NA, Kalden JR, van de Winkel JG: Clinical relevance of Fc γ receptor polymorphisms. Ann. NY Acad. Sci. 815, 282-295 (1997).
162. Hennino A, Berard F, Guillot I et al.: Pathophysiology of urticaria. Clin. Rev. Allergy Immunol. 30, 3-11 (2006).
163. Mousli M, Hugli TE, Landry Y, Bronner C: Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology 27, 1-11 (1994).
164. Marone G, Spaclarc, G, de Marino V, Aliperta M, Triggiani M. Immunopharmacology of human mast cells and basophilis. Int. J. Clin. Lab. Res. 28, 12-22 (1998).
165. Preuss CV, Wood TC, Szumlanski CL et al.: Human histamine N-methyltransferase pharmacogenetics: common genetic poiymorphisms that alter activity. Mol. Pharmacol. 53, 708-717 (1998).
166. Zarn JA, Bruschweiler BJ, Schlatter JR: Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 α-demethylase and aromatase. Environ. Health Perspect. 111, 255-261 (2003).
167. Albengres E, le Louet H, Tillement JP: Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 18, 83-97 (1998).
168. Pea F, Furlanut M: Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin. Pharmacokinet. 40, 833-868 (2001).
169. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38, 111-180 (2000).
170. Yoshida Y, Aoyama Y: Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cervisiae microsomes. Biochem Pharmacol. 36, 229-235 (1987).
171. Schuster I: The interaction of representative members from two classes of antimycotics - the azoles and the allylamines - with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica 15, 529-546 (1985)
172. Shakeri-Nejad K, Stahmann R: Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin. Pharmacother. 7, 639-651 (2006).
173. Saad AH, Depestel DD, Carver PL: Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26, 1730-1744 (2006).
174. Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull. 28, 1813-1816 (2005).
175. Niwa T, Shiraga, T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 28, 1805-1808 (2005).
176. 1 values and impact of CYP3A5 expression. Drug Metab. Dispos. 27, 180-187 (1999).
177. Abdel-Rahman SM, Marcucci K, Boge T et al.: Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab. Dispos. 27, 770-775 (1999).
178. Wang DS, Jonker JW, Kato Y et al.: Involvement of organic cation
179. Meiet A, Assrir N, Jean P et al.: Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch. Biochem. Biophys. 409, 80-91 (2003).
180. Williams PA, Cosme J, Sridhar V, Johnson EF, Mcree DE: Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell. 5, 121-131 (2000).
181. Cupp-Vickery JR, Garcia C, Hofacre A, Mcgee-Estrada K: Ketooonazole-induced conformational changes in the active site of cytochrome P450eryF. J. Mol. Biol. 311, 101-110 (2001).
182. Nitahara Y, Kishimoto K, Yabusaki Y et al.: The amino acid residues affecting the activity and azole susceptibility of rat CYP51 (sterol 14-demethylase, P450). J. Biochem. (Tokyo) 129, 761-768 (2001).
183. Hsu, I, Spinler SA, Johnson NE: Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann. Pharmacother. 29, 743-759 (1995).
184. Martin C, Berridge G, Higgins CF et al.: Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58, 624-632 (2000).
185. Loo TW, Clarke DM: Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J. Biol Chem. 275, 39272-39278 (2000).
186. Wang RB, Kuo CL, Lien LL, Lien EJ: Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther. 28, 203-228 (2003).
187. Schwab M, Eichelbaum M, Fromm, MF: Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307 (2003).
188. Lin E, Hwang Y, Liang KH, Chen EY: Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics 8, 75-83 (2007).
189. International HapMap Consortium: A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
190. Chanock SJ, Manolio T, Boehnke M et al.: Replicating genotype-phenotype associations. Nature 447, 655-660 (2007).
191. Hunter DJ, Thomas G, Hoover RN, Chanock SJ: Scanning the horizon: what is the future of genome-wide association studies in accelerating discoveries in cancer etiology and prevention? Cancer Causes Control 18, 479-484 (2007).
192. Easton DF, Pooley KA, Dunning AM et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007).
193. Hunter DJ, Kraft P, Jacobs KB et al.: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870-874 (2007).
194. Stacey SN, Manolescu A, Sulem, P et al.: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39, 865-869 (2007).
195. Tomlinson I, Webb E, Carvajal-Carmona L et al.: A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39, 984-988 (2007).
196. Zanke BW, Greenwood CM, Rangrej J et al.: Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39, 989-994 (2007).
197. Gudmundsson J, Sulem P, Manolescu A et al.: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631-637 (2007).
198. Yeager M, Orr N, Hayes RB et al.: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007).
199. Helgadottir A, Thorleifsson G, Manolescu A et al.: A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 1491-1493 (2007).
200. McPherson R, Pertsemlidis A, Kavaslar N et al.: A common allele on chromosome 9 associated with coronary heart disease. Science 316, 1488-1491 (2007).
201. Saxena R, Voight BF, Lyssenko, V et al.: Genome-wide association analysis identifies loci for Type 2 diabetes and triglyceride levels. Science 316, 1331-1336 (2007).
202. Scott LJ, Mohlke KL, Bonnycastle LL et al.: A genome-wide association study of Type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341-1345 (2007).
203. Todd JA, Walker NM, Cooper JD et al.: Robust associations of four new chromosome regions from genome-wide analyses of Type 1 diabetes. Nat. Genet. 39, 857-864 (2007).
204. Zeggini E, Weedon MN, Lindgren CM et al.: Replication of genome-wide association signals in UK samples reveals risk loci for Type 2 diabetes. Science 316, 1336-1341 (2007).
205. Parkes M, Barrett JC, Prescott NJ et al.: Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 39, 830-832 (2007).
206. Haiman CA, Le Marchand L, Yamamato J et al.: A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 39, 954-956 (2007).
207. Haiman CA, Patterson N, Freedman ML et al.: Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638-644 (2007).
208. Nebert DW, Vesell ES: Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol. Sci. 27, 580-586 (2006).
209. Giacomini KM, Krauss RM, Roden DM et al.: When good drugs go bad. Nature 446, 975-977 (2007).